Deliverables from Metabolomics in Kidney Disease: Adenine, New Insights and Implication for Clinical Decision Making

Am J Nephrol. 2024 Mar 3. doi: 10.1159/000538051. Online ahead of print.ABSTRACTBACKGROUND: Chronic kidney disease (CKD) presents a persistent global health challenge, characterized by complex pathophysiology and diverse progression patterns. Metabolomics has emerged as a valuable tool in unraveling the intricate molecular mechanisms driving CKD progression.SUMMARY: This comprehensive review provides a summary of recent progress in the field of metabolomics in kidney disease with a focus on spatial metabolomics to shed important insights to enhancing our understanding of CKD progression, emphasizing its transformative potential in early disease detection, refined risk assessment, and the development of targeted interventions to improve patient outcomes.KEY MESSAGE: Through an extensive analysis of metabolic pathways and small molecule fluctuations, bulk and spatial metabolomics offer unique insights spanning the entire spectrum of CKD, from early stages to advanced disease states. Recent advances in metabolomics technology have enabled spatial identification of biomarkers to provide breakthrough discoveries in predicting CKD trajectory and enabling personalized risk assessment. Furthermore, metabolomics can help decipher the complex molecular intricacies associated with kidney diseases for exciting novel therapeutic approaches. A recent example is the identification of adenine as a key marker of kidney fibrosis for diabetic kidney disease using both untargeted and targeted bu...
Source: American Journal of Nephrology - Category: Urology & Nephrology Authors: Source Type: research